Study Examines ImprimisRx’s Proprietary Klarity-C for Treatment of Signs and Symptoms of Dry Eye Disease
ImprimisRx, a wholly owned subsidiary of Harrow Health, announced that a study of its Klarity-C Drops (cyclosporine 0.1% ophthalmic emulsion PF) has been published in the peer-reviewed journal, Clinical Ophthalmology.1 Klarity-C is a compounded preservative-free cyclosporine eye drop that contains an emulsion with chondroitin sulfate and the active ingredient cyclosporine 0.1%, which has long been used to improve tear quality.2-4
“We’re pleased with the outstanding results of this multicenter retrospective study, which illuminate the clinical benefits that twice-daily treatment with our proprietary Klarity-C formulation may offer patients suffering from signs and symptoms of dry eye. More and more U.S. eye care professionals are recognizing that Klarity-C is an important prescribing choice for the millions of patients suffering with the discomfort and dissatisfaction associated with many other treatment options,” ImprimisRx President John Saharek said in a company news release. “We developed Klarity-C as an easy-to-use, preservative-free, affordable option that requires no insurance company prior authorizations, manufacturer coupons or rebate forms. We believe this study, performed by three renowned ophthalmologists with extensive dry eye disease pedigrees, supports the positive experiences of the many tens of thousands of patients who have been prescribed Klarity‑C.”
Klarity-C is compounded in a 503B FDA-registered and inspected outsourcing facility and is protected by patents issued in the United States and abroad.
Summary of the Study
In this multicenter retrospective study of 50 adult patients (100 eyes), dry eye disease was defined as an ocular surface disease index (OSDI) score over 12 or a corneal staining grade over 1. All patients were treated with Klarity-C. At 3 months, mean OSDI scores improved significantly (38.19 vs 24.18, P<0.001), as did the mean corneal staining grades (3.62 vs 2.20, P<0.001). Based on OSDI scores, the number of patients with severe dry eye dropped from 31 to 10, and 17 reached the normal range. Eyes with corneal staining grades of 2 or 3 dropped from 21 to 8; 50 eyes had no corneal staining. No adverse events were observed.
The complete study is now available online.
References
1Matossian C, Trattler W, Loh J. Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion. Clin Ophthalmol. 2021;15:1979-1984.
2Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005;112(10):1790–1794.
3Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology. 2000;107(5):967–974.
4Wirta DL, Torkildsen GL, Moreira HR, et al. A Clinical Phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease. Ophthalmology. 2019;126(6):792–800.